Denmark’s medical cannabis sales took a breather in 2022 after experiencing consistent growth for half a decade, according to new data from the Danish Health and Medicines Authority.
Argentina launched a national regulatory agency for the hemp and medical marijuana industries, aiming to capitalize on the domestic and international markets.
Medical marijuana companies in Denmark attracted external capital of more than 1.5 billion Danish kroner ($217 million), including founders’ own investments, which works out to an average of $6 million per business.
Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the launch of GW Pharmaceuticals’ cannabis drug Epidiolex.
Argentinian authorities published a new decree aiming to address the shortcomings of the rules governing the country’s medical cannabis sector, which has largely failed to materialize since an initial law and decree were approved in 2017.
